ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 107 | Juvenile idiopathic arthritis | 2 |
107. Juvenile idiopathic arthritis
Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-023802-10-NL (EUCTR) | 07/05/2012 | 07/11/2011 | Study Evaluation of the Long Term Safety of Etanercept In 3 Sub-typesof Childhood Arthritis | AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1 3338 WW(B1801014) - Clipper 2 | Oligoarticular juvenile idiopathic arthritis, enthesistis related arthritis, or psoriatic arthritis MedDRA version: 20.0;Level: PT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico INN or Proposed INN: ETANERCEPT Other descriptive name: ETANERCEPT Trade Name: ENBREL 50 mg solución inyectable en jeringas precargadas INN or Proposed INN: ETANERCEPT Other descriptive name: ETANERCEPT | Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States | NULL | Not Recruiting | Female: yes Male: yes | 123 | Phase 3 | Serbia;Slovenia;Slovakia;Spain;Lithuania;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico;Poland;Belgium;Australia;Netherlands;Germany;Latvia;Norway | ||
| 2 | EUCTR2010-023802-10-ES (EUCTR) | 15/09/2011 | 12/07/2011 | Study Evaluation of the Long Term Safety of Etanercept In 3 Sub-typesof Childhood Arthritis | AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1 3338 WW(B1801014) - Clipper 2 | Oligoarticular juvenile idiopathic arthritis, enthesistis related arthritis, or psoriatic arthritis MedDRA version: 14.0;Level: LLT;Classification code 10059176;Term: Juvenile idiopathic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico INN or Proposed INN: ETANERCEPT Other descriptive name: ETANERCEPT Trade Name: ENBREL 50 mg solución inyectable en jeringas precargadas INN or Proposed INN: ETANERCEPT Other descriptive name: ETANERCEPT | PFIZER, S.L.U. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 123 | Hungary;Colombia;Germany;Netherlands;Norway;France;Italy;Latvia;Australia;Lithuania;Slovakia;Russian Federation;Czech Republic;Serbia;Slovenia;Belgium;Mexico;Spain;Poland |